180 related articles for article (PubMed ID: 30566387)
1. Improved Modeling of Plutonium-DTPA Decorporation.
Dumit S; Avtandilashvili M; Strom DJ; McComish SL; Tabatadze G; Tolmachev SY
Radiat Res; 2019 Feb; 191(2):201-210. PubMed ID: 30566387
[TBL] [Abstract][Full Text] [Related]
2. The CONRAD approach to biokinetic modeling of DTPA decorporation therapy.
Breustedt B; Blanchardon E; Bérard P; Fritsch P; Giussani A; Lopez MA; Luciani A; Nosske D; Piechowski J; Schimmelpfeng J; Sérandour AL
Health Phys; 2010 Oct; 99(4):547-52. PubMed ID: 20838097
[TBL] [Abstract][Full Text] [Related]
3. Validation of a system of models for plutonium decorporation therapy.
Dumit S; Avtandilashvili M; McComish SL; Strom DJ; Tabatadze G; Tolmachev SY
Radiat Environ Biophys; 2019 May; 58(2):227-235. PubMed ID: 30627772
[TBL] [Abstract][Full Text] [Related]
4. Development of a New Chelation Model: Bioassay Data Interpretation and Dose Assessment after Plutonium Intake via Wound and Treatment with DTPA.
Dumit S; Miller G; Klumpp JA; Poudel D; Bertelli L; Waters TL
Health Phys; 2020 Dec; 119(6):715-732. PubMed ID: 33196524
[TBL] [Abstract][Full Text] [Related]
5. Biokinetic modelling of DTPA decorporation therapy: the CONRAD approach.
Breustedt B; Blanchardon E; Berard P; Fritsch P; Giussani A; Lopez MA; Luciani A; Nosske D; Piechowski J; Schimmelpfeng J; Sérandour AL
Radiat Prot Dosimetry; 2009 Feb; 134(1):38-48. PubMed ID: 19351653
[TBL] [Abstract][Full Text] [Related]
6. Developing a physiologically based approach for modeling plutonium decorporation therapy with DTPA.
Kastl M; Giussani A; Blanchardon E; Breustedt B; Fritsch P; Hoeschen C; Lopez MA
Int J Radiat Biol; 2014 Nov; 90(11):1062-7. PubMed ID: 24844369
[TBL] [Abstract][Full Text] [Related]
7. Simplified structure of a new model to describe urinary excretion of plutonium after systemic, liver or pulmonary contamination of rats associated with Ca-DTPA treatments.
Fritsch P; Sérandour AL; Grémy O; Phan G; Tsapis N; Abram MC; Renault D; Fattal E; Benech H; Deverre JR; Poncy JL
Radiat Res; 2009 Jun; 171(6):674-86. PubMed ID: 19580474
[TBL] [Abstract][Full Text] [Related]
8. Circulatory kinetics of intravenously injected 238Pu(IV) citrate and 14C-CaNa3-DTPA in mice: comparison with rat, dog, and reference man.
Durbin PW; Kullgren B; Schmidt CT
Health Phys; 1997 Feb; 72(2):222-35. PubMed ID: 9003707
[TBL] [Abstract][Full Text] [Related]
9. Plutonium-DTPA Model Application with USTUR Case 0269.
Konzen K; Brey R; Miller S
Health Phys; 2016 Jan; 110(1):59-65. PubMed ID: 26606066
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo assessment of plutonium speciation and decorporation in blood and target retention tissues after a systemic contamination followed by an early treatment with DTPA.
Sérandour AL; Grémy O; Fréchou M; Renault D; Poncy JL; Fritsch P
Radiat Res; 2008 Aug; 170(2):208-15. PubMed ID: 18666819
[TBL] [Abstract][Full Text] [Related]
11. Ustur Case 0846: Modeling Americium Biokinetics after Intensive Decorporation Therapy.
Breustedt B; Avtandilashvili M; McComish SL; Tolmachev SY
Health Phys; 2019 Aug; 117(2):168-178. PubMed ID: 30489383
[TBL] [Abstract][Full Text] [Related]
12. Ustur whole body case 0269: demonstrating effectiveness of i.v. CA-DTPA for Pu.
James AC; Sasser LB; Stuit DB; Glover SE; Carbaugh EH
Radiat Prot Dosimetry; 2007; 127(1-4):449-55. PubMed ID: 18227077
[TBL] [Abstract][Full Text] [Related]
13. Decorporation approach following rat lung contamination with a moderately soluble compound of plutonium using local and systemic Ca-DTPA combined chelation.
Grémy O; Tsapis N; Bruel S; Renault D; Van der Meeren A
Radiat Res; 2012 Sep; 178(3):217-23. PubMed ID: 22799632
[TBL] [Abstract][Full Text] [Related]
14. Three plutonium chelation cases at Los Alamos National Laboratory.
Bertelli L; Waters TL; Miller G; Gadd MS; Eaton MC; Guilmette RA
Health Phys; 2010 Oct; 99(4):532-8. PubMed ID: 20838095
[TBL] [Abstract][Full Text] [Related]
15. Predicting plutonium decorporation efficacy after intravenous administration of DTPA formulations: Study of pharmacokinetic-pharmacodynamic relationships in rats.
Phan G; Le Gall B; Deverre JR; Fattal E; Bénech H
Pharm Res; 2006 Sep; 23(9):2030-5. PubMed ID: 16951998
[TBL] [Abstract][Full Text] [Related]
16. Evaluating Plutonium Intake and Radiation Dose Following Extensive Chelation Treatment.
Dumit S; Avtandilashvili M; Tolmachev SY
Health Phys; 2019 Aug; 117(2):156-167. PubMed ID: 29750674
[TBL] [Abstract][Full Text] [Related]
17. Structure of a single model to describe plutonium and americium decorporation by DTPA treatments.
Fritsch P; Sérandour AL; Grémy O; Phan G; Tsapis N; Fattal E; Benech H; Deverre JR; Poncy JL
Health Phys; 2010 Oct; 99(4):553-9. PubMed ID: 20838098
[TBL] [Abstract][Full Text] [Related]
18. Modelling DTPA therapy following Am contamination in rats.
Kastl M; Grémy O; Lamart S; Giussani A; Li WB; Hoeschen C
Radiat Environ Biophys; 2023 Nov; 62(4):483-495. PubMed ID: 37831188
[TBL] [Abstract][Full Text] [Related]
19. Targeting of diethylene triamine pentaacetic acid encapsulated in liposomes to rat liver: an effective strategy to prevent bone deposition and increase urine elimination of plutonium in rats.
Phan G; Ramounet-Le Gall B; Manceau J; Fanet M; Benech H; Fritsch P; Fattal E; Deverre JR
Int J Radiat Biol; 2004 Jun; 80(6):413-22. PubMed ID: 15362694
[TBL] [Abstract][Full Text] [Related]
20. Decorporation of Pu/Am Actinides by Chelation Therapy: New Arguments in Favor of an Intracellular Component of DTPA Action.
Grémy O; Laurent D; Coudert S; Griffiths NM; Miccoli L
Radiat Res; 2016 Jun; 185(6):568-79. PubMed ID: 27195610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
